Rachel McMinn, CEO of Neurogene NGNE, has filed 1 purchase and 1 sale on the open market. Over the past 12 months that comes to a net sale of $74K. The latest trade was on 03/26.

RM

RM

Rachel McMinn

CEO

Company

Neurogene NGNE

First filing

24/03/14

Trades

7 trades

Buys / sales

1 / 1

12-month net buying

−$74K

Last trade

03/26

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
NeurogeneNGNE	Open-market sale10b5-1 plan	03/26	03/30	3,352 sh	$22.07	$73,978.64	−0.2%
NeurogeneNGNE	Open-market buy	24/11/22	24/11/25	47,500 sh	$20.40	$969,000	+3.8%